Karyopharm Therapeutics Inc (NASDAQ: KPTI) kicked off on Friday, down -8.96% from the previous trading day, before settling in for the closing price of $1.34. Over the past 52 weeks, KPTI has traded in a range of $0.62-$4.87.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 52.21% over the past five years. While this was happening, its average annual earnings per share was recorded 1.62%. With a float of $105.74 million, this company’s outstanding shares have now reached $114.92 million.
Let’s look at the performance matrix of the company that is accounted for 325 employees.
Karyopharm Therapeutics Inc (KPTI) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Karyopharm Therapeutics Inc is 8.11%, while institutional ownership is 66.37%. The most recent insider transaction that took place on Apr 04 ’24, was worth 4,596. In this transaction President and CEO of this company sold 3,563 shares at a rate of $1.29, taking the stock ownership to the 1,157,273 shares. Before that another transaction happened on Mar 05 ’24, when Company’s President and CEO sold 3,573 for $1.30, making the entire transaction worth $4,645. This insider now owns 1,160,836 shares in total.
Karyopharm Therapeutics Inc (KPTI) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 31.23 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 1.62% per share during the next fiscal year.
Karyopharm Therapeutics Inc (NASDAQ: KPTI) Trading Performance Indicators
Take a look at Karyopharm Therapeutics Inc’s (KPTI) current performance indicators. Last quarter, stock had a quick ratio of 3.32. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.96.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.25, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -1.01 in one year’s time.
Technical Analysis of Karyopharm Therapeutics Inc (KPTI)
Karyopharm Therapeutics Inc (NASDAQ: KPTI) saw its 5-day average volume 0.92 million, a negative change from its year-to-date volume of 1.67 million. As of the previous 9 days, the stock’s Stochastic %D was 12.68%. Additionally, its Average True Range was 0.14.
During the past 100 days, Karyopharm Therapeutics Inc’s (KPTI) raw stochastic average was set at 45.22%, which indicates a significant increase from 8.51% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 88.58% in the past 14 days, which was lower than the 116.52% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3500, while its 200-day Moving Average is $1.2056. Nevertheless, the first resistance level for the watch stands at $1.3167 in the near term. At $1.4133, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.4817. If the price goes on to break the first support level at $1.1517, it is likely to go to the next support level at $1.0833. Assuming the price breaks the second support level, the third support level stands at $0.9867.
Karyopharm Therapeutics Inc (NASDAQ: KPTI) Key Stats
The company with the Market Capitalisation of 140.39 million has total of 115,067K Shares Outstanding. Its annual sales at the moment are 146,030 K in contrast with the sum of -143,100 K annual income. Company’s last quarter sales were recorded 33,750 K and last quarter income was -41,840 K.
